• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation.

作者信息

Aalbers J

出版信息

Cardiovasc J Afr. 2011 Jul-Aug;22(4):220.

PMID:21881695
Abstract
摘要

相似文献

1
South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation.南非华法林控制不佳引发了房颤患者使用华法林相较于其他抗凝治疗是否更具优势的疑问。
Cardiovasc J Afr. 2011 Jul-Aug;22(4):220.
2
Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.预测房颤患者在住院环境中使用华法林的因素。
Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.
3
Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.心房颤动患者 INR 的变异性及其与死亡率、卒中、出血和住院的关系。
Thromb Res. 2012 Jan;129(1):32-5. doi: 10.1016/j.thromres.2011.07.004. Epub 2011 Aug 17.
4
Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.评估华法林在治疗范围内的时间对土耳其心房颤动患者结局的影响：来自观察性前瞻性WATER注册研究的观点
Cardiol J. 2015;22(5):567-75. doi: 10.5603/CJ.a2015.0035. Epub 2015 Jun 23.
5
Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.反对观点：“华法林应是老年房颤患者血栓预防的首选药物”。关于老年房颤患者使用口服抗凝治疗的注意事项。
Thromb Haemost. 2008 Jul;100(1):16-7. doi: 10.1160/TH08-06-0343.
6
Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.正方观点：“华法林应该是老年房颤患者血栓预防的首选药物”。为什么华法林确实应该成为老年房颤患者预防中风的首选药物。
Thromb Haemost. 2008 Jul;100(1):14-5. doi: 10.1160/TH08-06-0344.
7
Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment.心房颤动的抗栓治疗与患者的治疗偏好
Age Ageing. 2005 Jan;34(1):1-3. doi: 10.1093/ageing/afi008.
8
Stroke in heart failure: atrial fibrillation revisited?心力衰竭中的中风：重新审视心房颤动？
J Stroke Cerebrovasc Dis. 2010 Jan;19(1):1-2. doi: 10.1016/j.jstrokecerebrovasdis.2009.09.002.
9
Oral anticoagulation and stroke in atrial fibrillation.心房颤动中的口服抗凝治疗与卒中
N Engl J Med. 2003 Dec 11;349(24):2360-1; author reply 2360-1.
10
Atrial fibrillation and anticoagulation therapy: different race, different risk, and different management?心房颤动与抗凝治疗：不同种族、不同风险及不同管理方式？
Circ J. 2011;75(6):1314-5. doi: 10.1253/circj.cj-11-0402. Epub 2011 Apr 29.

引用本文的文献

1
Atrial fibrillation among the black population in a Ugandan tertiary hospital.乌干达一家三级医院黑人患者中的房颤情况
Int J Gen Med. 2016 Jun 8;9:191-8. doi: 10.2147/IJGM.S100637. eCollection 2016.
2
Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa.南非开普敦一家城市医院接受华法林治疗患者的概况及抗凝治疗结果
Afr J Prim Health Care Fam Med. 2016 May 31;8(1):e1-8. doi: 10.4102/phcfm.v8i1.1032.
3
Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options.
撒哈拉以南非洲地区的心房颤动：流行病学、未满足的需求及治疗选择
Int J Gen Med. 2015 Jul 31;8:231-42. doi: 10.2147/IJGM.S84537. eCollection 2015.
4
Potential use of NOACs in developing countries: pros and cons.在发展中国家非维生素K拮抗剂口服抗凝药的潜在应用：利弊
Eur J Clin Pharmacol. 2014 Jul;70(7):817-28. doi: 10.1007/s00228-014-1693-y. Epub 2014 May 11.
5
Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience.华法林禁忌的心房颤动患者的左心耳封堵术：南非的初步经验。
Cardiovasc J Afr. 2013 May;24(4):107-9. doi: 10.5830/CVJA-2013-018.